EyeGene Inc. (KOSDAQ:185490)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,950.00
+20.00 (1.04%)
At close: Sep 23, 2026

EyeGene Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4,4833,5673,3563,1255,2933,242
Revenue Growth
13.04%6.29%7.37%-40.96%63.27%-3.61%
Gross Profit
1,2051,0881,1471,8652,6871,465
Operating Income
-12,466-9,935-13,254-27,086-24,089-35,004
Net Income
-17,552-15,706-12,128-21,106-25,953-34,569
Earnings Per Share
-486.92-561.70-449.00-975.06-1210.28-2053.18
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
38,67545,49732,54755,36866,45585,357
Total Debt
510.42560.242,4412,1512,3973,943
Net Cash (Debt)
38,16544,93630,10753,21764,05881,413
Net Cash Growth
40.37%49.26%-43.43%-16.92%-21.32%434.64%
Net Cash Per Share
1058.711607.061114.592458.552987.224298.37

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-9,466-5,981-12,171-20,120-18,568-30,004
Capital Expenditures
-96.38-102.69-1,514-1,385-767.86-2,378
Free Cash Flow
-9,562-6,084-13,685-21,506-19,336-32,382
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
26.87%30.50%34.18%59.69%50.76%45.19%
Operating Margin
-278.06%-278.53%-394.95%-866.63%-455.07%-1079.66%
Pretax Margin
-468.99%-534.85%-384.30%-717.68%-522.48%-1068.84%
Profit Margin
-391.52%-440.34%-361.41%-675.30%-490.29%-1066.25%
FCF Margin
-213.30%-170.57%-407.82%-688.10%-365.27%-998.79%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
18.8021.0820.6229.3120.41126.13